Such discrepancies highlight the need for improved strategies in assessing HER2 status throughout the entire metastatic tumor burden that accurately assess for heterogeneous expression to optimize treatment selection for patients with metastatic HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast cancer.